Finanzen von Moleculin Biotech Inc (MBRX)MBRXMoleculin Biotech Inc

Evaluating the bottom line, Moleculin Biotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1906.92%, provide a clear picture of how effectively MBRX converts its operational activities into shareholder value.

In the context of the broader market, MBRX competes directly with industry leaders such as QNRX and KALA. With a market capitalization of $13.16M, it holds a significant position in the sector. When comparing efficiency, MBRX's gross margin of N/A stands against QNRX's N/A and KALA's N/A. Such benchmarking helps identify whether Moleculin Biotech Inc is trading at a premium or discount relative to its financial performance.

Moleculin Biotech has shown a net income loss of $14.61 million in Q1 2026, but it reported a positive net income of $15.45 million in Q4 2025, indicating potential for recovery. The current ratio is 0.94, suggesting liquidity issues.